Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA - Free Report) in a research report released on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $25.00 target price on the stock.
Several other equities analysts have also weighed in on the stock. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. UBS Group cut their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Buy" and a consensus target price of $24.50.
Get Our Latest Analysis on TEVA
Teva Pharmaceutical Industries Trading Down 4.3%
Shares of Teva Pharmaceutical Industries stock traded down $0.76 on Wednesday, hitting $16.77. 19,852,269 shares of the company's stock traded hands, compared to its average volume of 10,105,614. The company has a fifty day moving average of $15.52 and a two-hundred day moving average of $17.37. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $22.80. The company has a market capitalization of $19.01 billion, a price-to-earnings ratio of -11.57, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.48 EPS. As a group, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Institutional investors have recently added to or reduced their stakes in the company. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter worth $44,000. Golden State Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries in the first quarter worth $39,000. New Age Alpha Advisors LLC bought a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Finally, Ameliora Wealth Management Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $66,000. 54.05% of the stock is owned by institutional investors.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
